Legal & RegulatoryEvent: September 1, 2026
Optheras A/S is enrolled in the FDA's TAP program following its Breakthrough Device Designation.
Published
Signal category
Legal & Regulatory
Quote
“Enrolled in the FDA's TAP program, following our Breakthrough Device Designation”
— Thomas Alkeskjold|Optheras A/S team
Company
- Industry
- Medical Equipment Manufacturing
- Location
- Birkerød, DK
- Company size
- 26 employees
Optheras A/S was founded in 2022 and is part of T&W Medical A/S, former Widex group. Optheras' is founded by a team of urologist, regulatory experts, business executives and technology experts. Our mission is to increase the quality of life for patients living with bladder cancer, while supporting more efficient use of medical ressources. We are developing a new laser tool, that will change how this disease is handled.
Founded 2022